Showing results (1-10 of 2,092) with videos related to
Sort By:
Pageof 210
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1995
Immunoreactive human chorionic gonadotropin beta core fragment in human pituitaryR Hoermann, G Spoettl, P Berger, et al.The Journal of Clinical Endocrinology and Metabolism|July 1, 1990
Evidence for the presence of human chorionic gonadotropin (hCG) and free beta-subunit of hCG in the human pituitaryR Hoermann, G Spoettl, R Moncayo, et al.Clinical Chemistry|December 1, 1994
Immunological recognition and clinical significance of nicked human chorionic gonadotropin in testicular cancerR Hoermann, P Berger, G Spoettl, et al.The Clinical Investigator|November 1, 1993
Molecular heterogeneity of human chorionic gonadotropin in serum and urine from patients with trophoblastic tumorsR Hoermann, G Spoettl, M Grossmann, et al.Cancer Research|March 15, 1992
Immunoreactive human chorionic gonadotropin and its free beta subunit in serum and ascites of patients with malignant tumorsR Hoermann, A L Gerbes, G Spoettl, et al.Hormone Research|March 15, 2003
Tumor- and pregnancy-derived isoforms of human chorionic gonadotropin: biological and diagnostic relevanceC Lottersberger, R Hoermann, K Mann, et al.Journal of Endocrinological Investigation|May 1, 1993
Thyroid stimulation by placental factorsK Mann, R HoermannEuropean Journal of Clinical Investigation|November 1, 1995
Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignanciesM Grossmann, R Hoermann, P M Gocze, et al.European Journal of Clinical Investigation|February 1, 1994
Alpha-subunit and human chorionic gonadotropin-beta immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumoursM Grossmann, M E Trautmann, S Poertl, et al.Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 1, 1990
Evaluation of the ratio of T3 release stimulating antibodies to TSH-binding inhibiting antibodies during the course of Graves' diseaseR Hoermann, B Saller, K MannPageof 210